ahlam1399
04-08-2016, 11:21 PM
Biogen explores sale of hemophilia assets: sources
(Reuters) - Biogen Inc, one of the world's largest biotech**logy companies, is exploring a sale of its hemophilia treatments, as it increases its focus on core therapeutic areas, according to people familiar with the matter.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4ed18830/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=Oip9373vA**:RjcTu_4VIPY:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Oip9373vA**:RjcTu_4VIPY:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=Oip9373vA**:RjcTu_4VIPY:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Oip9373vA**:RjcTu_4VIPY:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=Oip9373vA**:RjcTu_4VIPY:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/Oip9373vA**
(Reuters) - Biogen Inc, one of the world's largest biotech**logy companies, is exploring a sale of its hemophilia treatments, as it increases its focus on core therapeutic areas, according to people familiar with the matter.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4ed18830/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=Oip9373vA**:RjcTu_4VIPY:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Oip9373vA**:RjcTu_4VIPY:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=Oip9373vA**:RjcTu_4VIPY:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Oip9373vA**:RjcTu_4VIPY:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=Oip9373vA**:RjcTu_4VIPY:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/Oip9373vA**